Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Generate Biomedicines, Inc.NASDAQ: GENB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization of $3.27M in Q1 FY2026
Q1 FY2026 depreciation & amortization was $3.27M.
Context
- Depreciation & amortization amounted to 41.3% of revenue in FY2025, down 33.7 pp from a year earlier.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 13.18M USD
- Year-over-year change
- -14.1%
- 1-year CAGR
- -14.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.18M | -14.1% |
| FY2024 | 2024-12-31 | 15.35M | — |
Depreciation & Amortization vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 depreciation & amortization of $13.18M is the 2nd highest of the 5 companies compared; the peer median is $9.05M.
- Its year-over-year change of -14.1% is the lowest of 5, against a peer median of -9.4%.
- Depreciation & amortization amounts to 41.3% of revenue for GENB, versus a peer median of 113.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.16M | -7.6% | -4.5% | 47.4% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $13.18M | -14.1% | — | 41.3% |
| LTM Mar 2026 | $11.4M | -12.6% | -3.4% | 620.8% | |
| LTM Mar 2026 | $6.7M | -8.9% | -4.0% | 6.7% | |
| LTM Mar 2026 | $2.35M | -9.8% | +26.6% | 180.4% | |
| Peer median (excluding GENB) | $9.05M | -9.4% | -3.7% | 113.9% | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 20.46M | 31.89M |
| Gross Margin | 100.0% | 100.0% |
| Research & Development | 175.31M | 224.7M |
| Selling, General & Admin | 42.09M | 42.26M |
| Operating Expenses | 217.4M | 266.96M |
| Depreciation & Amortization | 15.35M | 13.18M |
| EBITDA | (163.71M) | (208.49M) |
| EBITDA Margin | -800.2% | -653.7% |
| Operating Income | (196.94M) | (235.07M) |
| Operating Margin | -962.6% | -737.0% |
| Interest Income | 18.12M | 13.66M |
| Interest Expense | 2.12M | 1.14M |
| Other Income / Expenses | 15.77M | 12.26M |
| Income Before Tax | (181.17M) | (222.8M) |
| Pre-Tax Margin | -885.5% | -698.6% |
| Income Tax Expense | 212K | 163K |
| Net Income | (173.77M) | (203.15M) |
| Net Margin | -849.4% | -637.0% |
| EPS (Basic) | (1.68) | (4.98) |
| EPS (Diluted) | (1.68) | (4.98) |
| Weighted Avg Shares | 127.45M | 50.09M |
| Weighted Avg Shares (Diluted) | 127.45M | 50.09M |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.